KR20240154646A - 바이러스성 감염 치료를 위한 화합물 및 방법 - Google Patents
바이러스성 감염 치료를 위한 화합물 및 방법 Download PDFInfo
- Publication number
- KR20240154646A KR20240154646A KR1020247032560A KR20247032560A KR20240154646A KR 20240154646 A KR20240154646 A KR 20240154646A KR 1020247032560 A KR1020247032560 A KR 1020247032560A KR 20247032560 A KR20247032560 A KR 20247032560A KR 20240154646 A KR20240154646 A KR 20240154646A
- Authority
- KR
- South Korea
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound
- alkyl
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263315919P | 2022-03-02 | 2022-03-02 | |
| US63/315,919 | 2022-03-02 | ||
| US202263413748P | 2022-10-06 | 2022-10-06 | |
| US63/413,748 | 2022-10-06 | ||
| PCT/US2023/014293 WO2023167938A1 (en) | 2022-03-02 | 2023-03-01 | Compounds and methods for treatment of viral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240154646A true KR20240154646A (ko) | 2024-10-25 |
Family
ID=85772852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247032560A Pending KR20240154646A (ko) | 2022-03-02 | 2023-03-01 | 바이러스성 감염 치료를 위한 화합물 및 방법 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230322813A1 (https=) |
| EP (1) | EP4486746A1 (https=) |
| JP (1) | JP2025508943A (https=) |
| KR (1) | KR20240154646A (https=) |
| AU (1) | AU2023227470A1 (https=) |
| CA (1) | CA3243944A1 (https=) |
| TW (2) | TWI878811B (https=) |
| WO (1) | WO2023167938A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2524356T3 (es) | 2010-07-22 | 2014-12-05 | Gilead Sciences, Inc. | Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae |
| CA3059777C (en) | 2017-05-01 | 2023-02-21 | Gilead Sciences, Inc. | Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
| KR20220153619A (ko) | 2020-03-12 | 2022-11-18 | 길리애드 사이언시즈, 인코포레이티드 | 1'-시아노 뉴클레오사이드의 제조 방법 |
| IL300453A (en) | 2020-08-27 | 2023-04-01 | Gilead Sciences Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS |
| KR20240154647A (ko) | 2022-03-02 | 2024-10-25 | 길리애드 사이언시즈, 인코포레이티드 | 바이러스성 감염 치료를 위한 화합물 및 방법 |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
| CN119039322A (zh) * | 2023-09-19 | 2024-11-29 | 广东晨康生物科技有限公司 | 一种环碳酸酯核苷化合物的盐、晶体及其制备方法和应用 |
| CN119792537B (zh) * | 2025-01-22 | 2025-10-21 | 常州大学 | 利巴韦林与pd-1抑制剂联合用药物组合物及其应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ105499A0 (en) | 1999-06-18 | 1999-07-08 | Biota Scientific Management Pty Ltd | Antiviral agents |
| AUPR213700A0 (en) | 2000-12-18 | 2001-01-25 | Biota Scientific Management Pty Ltd | Antiviral agents |
| JP5030587B2 (ja) | 2003-06-26 | 2012-09-19 | バイオトロン・リミテッド | 抗ウイルスアシルグアニジン化合物および方法 |
| EP2826770B1 (en) | 2005-06-24 | 2018-09-12 | Biotron Limited | Acylguanidine compounds with antiviral activity |
| US20100254942A1 (en) | 2007-08-03 | 2010-10-07 | Biotron Limited | Hepatitis c antiviral compositions and methods |
| CA2881322A1 (en) | 2012-09-10 | 2014-03-13 | F. Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| SI3043865T1 (sl) | 2013-09-11 | 2021-04-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Metode in farmacevtski sestavki za zdravljenje virusne okužbe s hepatitisom B |
| EA201691261A1 (ru) | 2014-01-30 | 2016-11-30 | Ф. Хоффманн-Ля Рош Аг | Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b |
| AU2015226206B2 (en) | 2014-03-07 | 2017-03-16 | F. Hoffmann-La Roche Ag | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection |
| KR20160148715A (ko) | 2014-05-13 | 2016-12-26 | 에프. 호프만-라 로슈 아게 | B형 간염 바이러스 감염의 치료 또는 예방을 위한 신규한 다이하이드로퀴놀리진온 |
| WO2016012470A1 (en) | 2014-07-25 | 2016-01-28 | F. Hoffmann-La Roche Ag | New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid |
| BR112017002970B1 (pt) | 2014-08-14 | 2023-04-11 | F. Hoffmann-La Roche Ag | Novas piridazonas e triazinonas para o tratamento e profilaxia da infecção pelo vírus da hepatite b |
| US9637485B2 (en) | 2014-11-03 | 2017-05-02 | Hoffmann-La Roche Inc. | 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection |
| AR103222A1 (es) | 2014-12-23 | 2017-04-26 | Hoffmann La Roche | Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina |
| US9676793B2 (en) | 2014-12-23 | 2017-06-13 | Hoffmann-Laroche Inc. | Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same |
| CN107108610B (zh) | 2014-12-30 | 2019-06-04 | 豪夫迈·罗氏有限公司 | 用于治疗和预防肝炎b病毒感染的新的四氢吡啶并嘧啶和四氢吡啶并吡啶化合物 |
| CN107109497A (zh) | 2014-12-31 | 2017-08-29 | 豪夫迈·罗氏有限公司 | 通过实时PCR从细胞裂解物定量HBV cccDNA的高通量新方法 |
| MA41338B1 (fr) | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
| WO2016120186A1 (en) | 2015-01-27 | 2016-08-04 | F. Hoffmann-La Roche Ag | Recombinant hbv cccdna, the method to generate thereof and the use thereof |
| HK1244281B (zh) | 2015-02-11 | 2020-02-07 | F. Hoffmann-La Roche Ag | 治疗和预防乙型肝炎病毒感染的2-氧代-6，7-二氢苯并[a]喹嗪-3-甲酸衍生物 |
| WO2017184668A1 (en) * | 2016-04-20 | 2017-10-26 | Gilead Sciences, Inc. | Methods for treating flaviviridae virus infections |
| SG11201907034PA (en) | 2017-02-08 | 2019-08-27 | Biotron Ltd | Methods of treating influenza |
| JP2023512656A (ja) * | 2020-01-27 | 2023-03-28 | ギリアード サイエンシーズ， インコーポレイテッド | ＳＡＲＳ ＣｏＶ－２感染を治療するための方法 |
| TWI791193B (zh) * | 2020-02-18 | 2023-02-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| CN112778310B (zh) * | 2020-04-20 | 2025-05-30 | 中国科学院上海药物研究所 | 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用 |
| IL300453A (en) * | 2020-08-27 | 2023-04-01 | Gilead Sciences Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS |
| KR102918401B1 (ko) * | 2020-12-30 | 2026-01-26 | 서던 유니버시티 오브 사이언스 앤드 테크놀로지 | 코로나 바이러스 감염을 치료하기 위한 방법 및 변형된 뉴클레오사이드 |
| US20240166680A1 (en) * | 2021-04-15 | 2024-05-23 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Nucleoside analog and use thereof |
| CN114181258B (zh) * | 2021-12-29 | 2023-10-13 | 南京师范大学 | 用于抗病毒治疗的核苷类化合物及用途 |
| CN114437159B (zh) * | 2022-04-11 | 2022-06-28 | 佛山市晨康生物科技有限公司 | 一种环状碳酸酯核苷类化合物及其应用 |
-
2023
- 2023-03-01 KR KR1020247032560A patent/KR20240154646A/ko active Pending
- 2023-03-01 TW TW112107366A patent/TWI878811B/zh active
- 2023-03-01 EP EP23713504.1A patent/EP4486746A1/en active Pending
- 2023-03-01 TW TW114109499A patent/TW202525811A/zh unknown
- 2023-03-01 WO PCT/US2023/014293 patent/WO2023167938A1/en not_active Ceased
- 2023-03-01 CA CA3243944A patent/CA3243944A1/en active Pending
- 2023-03-01 AU AU2023227470A patent/AU2023227470A1/en active Pending
- 2023-03-01 JP JP2024551973A patent/JP2025508943A/ja active Pending
- 2023-03-01 US US18/115,895 patent/US20230322813A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4486746A1 (en) | 2025-01-08 |
| WO2023167938A1 (en) | 2023-09-07 |
| TW202525811A (zh) | 2025-07-01 |
| CA3243944A1 (en) | 2023-09-07 |
| TWI878811B (zh) | 2025-04-01 |
| JP2025508943A (ja) | 2025-04-10 |
| AU2023227470A1 (en) | 2024-08-29 |
| TW202345786A (zh) | 2023-12-01 |
| US20230322813A1 (en) | 2023-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11814406B2 (en) | Compounds and methods for treatment of viral infections | |
| TWI878811B (zh) | 用於治療病毒感染的化合物及方法 | |
| TWI867455B (zh) | 用於治療病毒感染的化合物及方法 | |
| JP2023531524A (ja) | １’－シアノヌクレオシド類似体及びその使用 | |
| WO2022046631A1 (en) | Phospholipid compounds and uses thereof | |
| WO2025072641A1 (en) | Compounds and methods for treatment of viral infections | |
| KR20240155326A (ko) | 항바이러스 화합물 및 이의 제조와 사용 방법 | |
| CN118786127A (zh) | 用于治疗病毒感染的化合物和方法 | |
| HK40115603A (en) | Compounds and methods for treatment of viral infections | |
| HK40096334A (en) | Compounds and methods for treatment of viral infections | |
| HK40096334B (en) | Compounds and methods for treatment of viral infections | |
| HK40113783A (zh) | 用於治疗病毒感染的化合物和方法 | |
| EA048943B1 (ru) | Соединения и способы лечения вирусных инфекций |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |